Drug Trial Radar · NCT05298787
A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program
Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jan 13, 2021
Primary completion
Aug 16, 2021
Study completion Aug 16, 2021
Sponsor
- Lead sponsor
- ReAlta Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety, tolerability, PK, and PD of single- and multiple-ascending doses of RLS-0071 in healthy adult subjects.
Conditions
- Healthy Volunteer
Interventions
RLS-0071Drug
RLS-0071 is administered as an IV infusion
Saline PlaceboDrug
Placebo is administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From initiation of study treatment (Day 1) through follow-up period (Day 30)
- Incidence of abnormal laboratory test resultsTime frame: From initiation of study treatment (Day 1) through follow-up period (Day 30)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.